Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Dermabase.it

Search results for "Rituxan"

A Phase III clinical study of Rituximab ( Rituxan ) met its primary endpoint of a greater proportion of Rituximab-treated patients achieving an American College of Rheumatology ( ACR ) 20 response at ...


Rituximab ( Rituxan ), a drug used to treat cancer, may also benefit people with lupus erythematosus who have complications of the central nervous system. Lupus is a disorder of the immune system i ...


Preliminary results from a large randomized clinical trial of Rituximab ( Rituxan ) in rheumatoid arthritis showed that a greater proportion of patients treated with a single course of Rituximab, with ...


The FDA ( U.S. Food and Drug Administration ) has approved the therapeutic antibody Rituxan ( Rituximab ) in combination with Methotrexate to reduce signs and symptoms in adult patients with moderatel ...


The 36% of patients with refractory systemic lupus erythematosus ( SLE or lupus ) remain stable after undergoing B-cell depletion therapy ( BCDT ) without needing further standard immunosuppressive ag ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis ( RA ). In particular, B cell depletion wi ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In particular, B cell depletion with the ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In particular, B cell depletion with the ...


Rheumatoid arthritis patients who failed to respond to initial treatment with Rituximab ( MabThera, Rituxan ) ( a chimeric monoclonal antibody against the protein CD20 ) can still be successfully re-t ...


The 18-month efficacy of a single course of Rituximab ( MabThera, Rituxan ) as compared with conventional immunosuppression with Cyclophosphamide followed by Azathioprine in patients with severe ( org ...